| Human immunodeficiency virus I infection
Intelence vs Rukobia
Side-by-side clinical, coverage, and cost comparison for human immunodeficiency virus i infection.Deep comparison between: Intelence vs Rukobia with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsRukobia has a higher rate of injection site reactions vs Intelence based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Rukobia but not Intelence, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Intelence
Rukobia
At A Glance
Oral
Twice daily
NNRTI
Oral
Twice daily
HIV-1 attachment inhibitor
Indications
- Human immunodeficiency virus I infection
- Human immunodeficiency virus I infection
Dosing
Human immunodeficiency virus I infection 200 mg (one 200 mg tablet or two 100 mg tablets) orally twice daily following a meal
Human immunodeficiency virus I infection 600 mg orally twice daily with or without food; swallow tablets whole, do not chew, crush, or split.
Contraindications
—
- Previous hypersensitivity to fostemsavir or any component of RUKOBIA
- Coadministration with strong CYP3A inducers, including enzalutamide, carbamazepine, phenytoin, rifampin, mitotane, and St John's wort (Hypericum perforatum)
Adverse Reactions
Most common (>=2%) Rash, peripheral neuropathy
Serious Severe skin reactions including Stevens-Johnson syndrome, toxic epidermal necrolysis, erythema multiforme, drug hypersensitivity reactions including DRESS, hepatic failure, rhabdomyolysis
Postmarketing Fatal cases of toxic epidermal necrolysis and Stevens-Johnson syndrome, severe hypersensitivity reactions including DRESS and hepatic failure
Most common (>=2%) Nausea, diarrhea, headache, abdominal pain, dyspepsia, fatigue, rash, sleep disturbance, immune reconstitution inflammatory syndrome, somnolence, vomiting
Serious Immune reconstitution inflammatory syndrome, QTc prolongation, hepatic transaminase elevations in patients with hepatitis B or C virus co-infection
Pharmacology
Etravirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that binds directly to HIV-1 reverse transcriptase and blocks RNA-dependent and DNA-dependent DNA polymerase activities by disrupting the enzyme's catalytic site.
HIV-1 attachment inhibitor; fostemsavir is a prodrug hydrolyzed to temsavir, which binds directly to the gp120 subunit of the HIV-1 envelope glycoprotein and selectively inhibits the interaction between the virus and cellular CD4 receptors, preventing viral attachment and subsequent entry into host cells.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Intelence
- Covered on 5 commercial plans
- PA (5/12) · Step Therapy (0/12) · Qty limit (11/12)
Rukobia
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (9/12) · Qty limit (11/12)
UnitedHealthcare
Intelence
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (4/8)
Rukobia
- Covered on 4 commercial plans
- PA (4/8) · Step Therapy (0/8) · Qty limit (2/8)
Humana
Intelence
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Rukobia
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (1/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableGood Days: HIV, AIDS Treatment & Prevention
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableGood Days: HIV, AIDS Treatment & Prevention
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
IntelenceView full Intelence profile
RukobiaView full Rukobia profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.